2012 American College of Rheumatology guidelines for management of gout. Part 2: Therapy and antiinflammatory prophylaxis of acute gouty arthritis

Saved in:
Bibliographic Details
Published inArthritis care & research (2010) Vol. 64; no. 10; pp. 1447 - 1461
Main Authors Khanna, Dinesh, Khanna, Puja P., Fitzgerald, John D., Singh, Manjit K., Bae, Sangmee, Neogi, Tuhina, Pillinger, Michael H., Merill, Joan, Lee, Susan, Prakash, Shraddha, Kaldas, Marian, Gogia, Maneesh, Perez‐Ruiz, Fernando, Taylor, Will, Lioté, Frédéric, Choi, Hyon, Singh, Jasvinder A., Dalbeth, Nicola, Kaplan, Sanford, Niyyar, Vandana, Jones, Danielle, Yarows, Steven A., Roessler, Blake, Kerr, Gail, King, Charles, Levy, Gerald, Furst, Daniel E., Edwards, N. Lawrence, Mandell, Brian, Schumacher, H. Ralph, Robbins, Mark, Wenger, Neil, Terkeltaub, Robert
Format Journal Article
LanguageEnglish
Published Hoboken, USA John Wiley & Sons, Inc 01.10.2012
Wiley-Blackwell
Subjects
Anti-Inflammatory Agents - therapeutic use
Arthritis, Gouty - drug therapy
Arthritis, Gouty - prevention & control
Biological and medical sciences
Colchicine - therapeutic use
Diseases of the osteoarticular system
Gout Suppressants - therapeutic use
Humans
Inflammatory joint diseases
Medical sciences
Metabolic diseases
Miscellaneous. Osteoarticular involvement in other diseases
Other metabolic disorders
Purines and pyrimidines (gout, hyperuricemia...)
Acute
Gout
Diseases of the osteoarticular system
Antiinflammatory agent
Rheumatology
Metabolic diseases
Arthritis
Uric acid
Microcristalline arthropathy
Prevention
Hyperuricemia
Treatment
Purine
Microcrystal
Online AccessGet full text

Cover

More Information
Bibliography:Dr. Mandell has received consultant fees, speaking fees, and/or honoraria (less than $10,000 each) from Savient, Novartis, and Pfizer.
Dr. Choi has served on the advisory boards (less than $10,000 each) for Takeda, URL, and Savient.
Dr. Dinesh Khanna has received consultant fees, speaking fees, and/or honoraria (less than $10,000 each) from Novartis and Ardea and (more than $10,000 each) from Takeda and Savient, and has served as a paid investment consultant for Guidepoint.
Dr. Edwards has received consultant fees, speaking fees, and/or honoraria (less than $10,000 each) from Savient, Takeda, Ardea, and Regeneron, and (more than $10,000) from Novartis, and has given expert testimony for Novartis.
Dr. Schumacher has received consultant fees (less than $10,000 each) from Pfizer, Regeneron, West‐Ward, and Ardea, and (more than $10,000) from Novartis.
Dr. Singh has received consultant fees, speaking fees, and/or honoraria (less than $10,000 each) from Ardea, Savient, Allergan, and Novartis, and (more than $10,000) from Takeda, and has received investigator‐initiated grants from Takeda and Savient.
Dr. Terkeltaub has received consultant fees (less than $10,000 each) from Takeda, Savient, Ardea, BioCryst, URL, Regeneron, Pfizer, Metabolex, Nuon, Chugai, EnzymeRx, Ajanta, Anadys, Celgene, Isis, and Prescription Solutions, and (more than $10,000) from Novartis, has received grant support from the VA San Diego Healthcare System and the NIH, and has served as a paid investment consultant for Leerink Swann, Medacorp, and Guidepoint.
Dr. Perez‐Ruiz has received consultant fees, speaking fees, and/or honoraria (less than $10,000 each) from Novartis, Menarini, and Savient, and (more than $10,000) from Ardea.
Dr. Pillinger has received speaking fees and/or honoraria (less than $10,000 each) from the RA Investigator Network, NY Downtown Hospital, Winthrop Hospital, and Einstein College of Medicine.
Dr. Niyyar has received honoraria (less than $10,000) from the American Society of Nephrology.
Dr. Kerr has served as a study investigator (more than $10,000 each) for Savient and Nuon.
Dr. Dalbeth has received consultant fees, speaking fees, and/or honoraria (less than $10,000 each) from Novartis, Takeda, and Ardea, has received research funding from Fonterra, and holds a patent from Fonterra for milk products for gout.
Dr. Puja P. Khanna has received speaking fees (less than $10,000) from Novartis and (more than $10,000) from Takeda, and has served on the advisory board for Novartis.
Dr. Lioté has received consultant fees, speaking fees, and/or honoraria (less than $10,000 each) from Novartis Global, Novartis France, and Ipsen, and has served as a paid investment consultant for Gerson Lehrman Group.
Drs. Dinesh Khanna, Puja P. Khanna, and FitzGerald contributed equally to this work.
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Instructional Material/Guideline-2
ObjectType-Feature-3
content type line 23
ISSN:2151-464X
2151-4658
DOI:10.1002/acr.21773